Physician profile
James E Loskot
NPI 1619074754
$4,968.09
in general payments reported to CMS, 2019-2025
21 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $599 · 2021: $569 · 2022: $784 · 2023: $740 · 2024: $874 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $753.90 | 2021-2025 | Tearcare System, Omni Surgical System |
| Alcon Vision LLC | $661.26 | 2019-2025 | Precision7, Rocklatan, Clareon Panoptix Pro |
| Tarsus Pharmaceuticals, INC. | $584.77 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $375.67 | 2020-2023 | |
| Tearlab Corp | $347.55 | 2020 | |
| Bausch & Lomb Americas INC. | $346.55 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Sun Pharmaceutical Industries INC. | $305.59 | 2022-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.13 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $250.55 | 2020-2023 | Acuvue |
| Oyster Point Pharma, INC. | $213.87 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $123.97 | 2022-2025 | Myday Contact Lens |
| Dompe US, INC. | $118.33 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $114.53 | 2024-2025 | Vevye |
| Rxsight INC | $110.10 | 2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $107.58 | 2022-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $91.61 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $84.50 | 2020 | |
| Aerie Pharmaceuticals, INC. | $33.14 | 2020-2021 | |
| Allergan, INC. | $28.37 | 2021 | |
| Thea Pharma INC. | $24.17 | 2023 | |
| Rayner Intraocular Lenses Limited | $20.95 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Loskot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.